http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Ca
-
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
-
Exelixis (EXEL) Announces Pact with Merck KGaA and Pfizer (PFE) to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
-
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur
-
Exelixis (EXEL) Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
-
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
-
Exelixis' (EXEL) Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX in Combination with OPDIVO as First-Line Treatment for Patients with Advanced RCC
-
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcino
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
-
Exelixis (EXEL) Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
-
Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
-
Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021
-
Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU
-
Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients
-
Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium
-
Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
-
OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the P
-
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021
-
Exelixis (EXEL) and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies
-
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
-
Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021
-
Exelixis (EXEL) Begins Phase 1 Trial Evaluating XL102 as Single Agent & in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors
-
Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
-
Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
-
Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
-
Exelixis (EXEL) Announces Cabozantinib Significantly Improved PFS in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
-
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid C
-
Exelixis (EXEL) In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational NDA for Phase 1 Clinical Trial in Advanced Solid Tumors
-
Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors
-
Exelixis (EXEL) In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
-
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
-
Exelixis (EXEL) Announces Partner Takeda Receives Approval in Japan for CABOMETYX for Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
-
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
-
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update
-
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November
-
Exelixis (EXEL), Takeda Pharma & Ono Pharma Report Submission of Supplemental Application for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) in Japan
-
Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Rena
-
Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors
-
Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020
-
Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma
-
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
-
Exelixis (EXEL) to Present Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Next-Gen Oral Tyrosine Kinase Inhibitor
-
Exelixis (EXEL) and Aurigene Announce Promising Preclinical Data to Be Presented at ENA Symposium Support Clinical Development of Novel CDK7 Inhibitor
-
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
-
Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor
